X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
plx4032 (103) 103
index medicus (78) 78
humans (75) 75
melanoma (72) 72
oncology (53) 53
braf (49) 49
mutation (45) 45
proto-oncogene proteins b-raf - genetics (44) 44
vemurafenib (44) 44
cancer (42) 42
metastatic melanoma (38) 38
melanoma - drug therapy (37) 37
proto-oncogene proteins b-raf - antagonists & inhibitors (33) 33
mutations (30) 30
cell line, tumor (29) 29
indoles - pharmacology (29) 29
sulfonamides - pharmacology (29) 29
melanoma - genetics (28) 28
melanoma - pathology (26) 26
indoles - therapeutic use (25) 25
resistance (25) 25
sulfonamides - therapeutic use (25) 25
pathway (23) 23
b-raf (19) 19
female (19) 19
animals (18) 18
kinase (18) 18
protein kinase inhibitors - pharmacology (18) 18
acquired-resistance (17) 17
article (17) 17
male (17) 17
proto-oncogene proteins b-raf - metabolism (17) 17
survival (17) 17
drug therapy (16) 16
skin neoplasms - drug therapy (16) 16
therapy (16) 16
antineoplastic agents - pharmacology (15) 15
inhibitor (15) 15
skin neoplasms - pathology (15) 15
adult (14) 14
dermatology (14) 14
malignant-melanoma (14) 14
proliferation (14) 14
skin neoplasms - genetics (14) 14
activation (13) 13
antineoplastic agents - therapeutic use (13) 13
gene mutations (13) 13
middle aged (13) 13
aged (12) 12
care and treatment (12) 12
cell proliferation - drug effects (12) 12
kinases (12) 12
mek (12) 12
melanoma - enzymology (12) 12
melanoma - metabolism (12) 12
neoplasms (12) 12
pharmacology & pharmacy (12) 12
braf inhibitor (11) 11
cell biology (11) 11
cells (11) 11
drug resistance, neoplasm (11) 11
genetic aspects (11) 11
phosphorylation (11) 11
raf (11) 11
apoptosis (10) 10
growth (10) 10
metastasis (10) 10
mice (10) 10
protein kinase inhibitors - therapeutic use (10) 10
sorafenib (10) 10
erk (9) 9
inhibition (9) 9
proteins (9) 9
research (9) 9
signal transduction (9) 9
signal transduction - drug effects (9) 9
skin cancer (9) 9
targeted therapy (9) 9
apoptosis - drug effects (8) 8
biochemistry & molecular biology (8) 8
cutaneous melanoma (8) 8
drug resistance (8) 8
drug resistance, neoplasm - drug effects (8) 8
health aspects (8) 8
map kinase signaling system - drug effects (8) 8
mutation - genetics (8) 8
neoplasm metastasis (8) 8
plx4720 (8) 8
raf inhibitors (8) 8
tumors (8) 8
aged, 80 and over (7) 7
analysis (7) 7
cell lines (7) 7
cell proliferation (7) 7
dabrafenib (7) 7
rg7204 (7) 7
sensitivity (7) 7
braf inhibitors (6) 6
braf mutation (6) 6
development and progression (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


NATURE, ISSN 0028-0836, 12/2010, Volume 468, Issue 7326, pp. 973 - U377
Activating B-RAF(V600E) (also known as BRAF) kinase mutations occur in similar to 7% of human malignancies and similar to 60% of melanomas(1). Early clinical... 
CELLS | MEK | PLX4032 | PATHWAY | MULTIDISCIPLINARY SCIENCES | KINASE | SENSITIVITY | BRAF | MUTATIONS | CRAF | CANCER
Journal Article
Annals of Pharmacotherapy, ISSN 1060-0280, 11/2011, Volume 45, Issue 11, pp. 1399 - 1405
Journal Article
Tetrahedron Letters, ISSN 0040-4039, 08/2012, Volume 53, Issue 32, pp. 4161 - 4165
Microwave-assisted total syntheses of the highly selective BRAF inhibitors PLX4720 and PLX4032 are reported. In addition to the synthesis of the title... 
BRAF | MAOS | PLX4032 | PLX4720 | Melanoma
Journal Article
Journal of Endocrinological Investigation, ISSN 0391-4097, 12/2013, Volume 36, Issue 11, pp. 1099 - 1104
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2012, Volume 366, Issue 8, pp. 707 - 714
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2012, Volume 366, Issue 3, pp. 207 - 215
Journal Article
Nature, ISSN 0028-0836, 09/2010, Volume 467, Issue 7315, pp. 596 - 599
B-RAF is the most frequently mutated protein kinase in human cancers. The finding that oncogenic mutations in BRAF are common in melanoma, followed by the... 
ACTIVATION | PATHWAY | MULTIDISCIPLINARY SCIENCES | MUTATION | KERATOACANTHOMAS | SENSITIVITY | SENESCENCE | SORAFENIB | HUMAN CANCER | PROGRESSION | BRAF(V600E) | Humans | Extracellular Signal-Regulated MAP Kinases - antagonists & inhibitors | Macaca fascicularis | Melanoma - enzymology | Substrate Specificity | Positron-Emission Tomography | Extracellular Signal-Regulated MAP Kinases - metabolism | Indoles - administration & dosage | Neoplasm Metastasis | Melanoma - genetics | Phosphorylation - drug effects | Mutant Proteins - antagonists & inhibitors | Proto-Oncogene Proteins B-raf - metabolism | Proto-Oncogene Proteins B-raf - chemistry | Sulfonamides - chemistry | Mutant Proteins - genetics | Models, Molecular | Rats | Mutant Proteins - metabolism | Melanoma - pathology | Mutation - genetics | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Xenograft Model Antitumor Assays | Animals | Indoles - adverse effects | MAP Kinase Signaling System - drug effects | Sulfonamides - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Mutant Proteins - chemistry | Alleles | Dogs | Sulfonamides - adverse effects | Indoles - therapeutic use | Indoles - chemistry | Sulfonamides - administration & dosage | Control | Gene mutations | Melanoma | Development and progression | Genetic aspects | Research | Health aspects | Protein kinases | Cancer | Proteins | Mutation | Kinases | Rodents | Index Medicus | targeted therapy | melanoma | BRAF | PLX4032 | biomarker | oncogene
Journal Article
Journal of Molecular Diagnostics, The, ISSN 1525-1578, 2013, Volume 15, Issue 2, pp. 220 - 226
The US Food and Drug Administration (FDA) approved vemurafenib to treat patients with metastatic melanoma harboring the BRAF c.1799T>A (p.V600E) mutation.... 
Pathology | METASTATIC MELANOMA | NRAS | PYROSEQUENCING ASSAY | GENE | PERFORMANCE | CUTANEOUS MELANOMA | KIT | MALIGNANT-MELANOMA | PATHOLOGY | INHIBITOR PLX4032 | VEMURAFENIB | Melanoma - diagnosis | Exons | Melanoma - genetics | Proto-Oncogene Proteins B-raf - genetics | Base Sequence | Humans | Mutation Rate | Retrospective Studies | Mutation | Index Medicus
Journal Article
Nature Reviews Clinical Oncology, ISSN 1759-4774, 07/2011, Volume 8, Issue 7, pp. 426 - 433
Journal Article
Journal Article
Cancer Research, ISSN 0008-5472, 04/2011, Volume 71, Issue 7, pp. 2750 - 2760
This study addresses the role of PTEN loss in intrinsic resistance to the BRAF inhibitor PLX4720. Immunohistochemical staining of a tissue array covering all... 
METASTATIC MELANOMA | APOPTOSIS | PROTEIN | ONCOLOGY | PHOSPHORYLATION | CUTANEOUS MELANOMA | RAF KINASE | CANCER | MEDIATES RESISTANCE | LINES | ERK | RNA, Small Interfering - genetics | Up-Regulation | Humans | Drug Resistance, Neoplasm | Phosphatidylinositol 3-Kinases - metabolism | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Proto-Oncogene Proteins - biosynthesis | Bcl-2-Like Protein 11 | Melanoma - genetics | Apoptosis Regulatory Proteins - genetics | Indoles - pharmacology | Proto-Oncogene Proteins c-akt - metabolism | Proto-Oncogene Proteins B-raf - metabolism | Apoptosis Regulatory Proteins - biosynthesis | Melanoma - metabolism | Proto-Oncogene Proteins - antagonists & inhibitors | PTEN Phosphohydrolase - deficiency | Membrane Proteins - genetics | PTEN Phosphohydrolase - biosynthesis | Proto-Oncogene Proteins - genetics | Melanoma - pathology | Sulfonamides - pharmacology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Membrane Proteins - biosynthesis | Membrane Proteins - antagonists & inhibitors | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Apoptosis Regulatory Proteins - antagonists & inhibitors | Cell Line, Tumor | Protein Kinase Inhibitors - pharmacology | Apoptosis - physiology | Mutation | RNA, Small Interfering - administration & dosage | Index Medicus | PTEN | melanoma | BRAF | PLX4032 | therapy | resistance
Journal Article
Pigment Cell & Melanoma Research, ISSN 1755-1471, 05/2014, Volume 27, Issue 3, pp. 495 - 501
The BRAF V600E mutation, which approaches 50% in human melanomas, constitutively activates pERK and contributes to disease progression. The BRAF V600E... 
Cells | Melanoma | Vemurafenib | PLX4032 | cell culture | melanoma | Murine BRafV600E | pERK | B6 syngeneic mouse model
Journal Article
by Wang, J and Chen, JJ and Miller, DD and Li, W
MOLECULAR CANCER THERAPEUTICS, ISSN 1535-7163, 01/2014, Volume 13, Issue 1, pp. 16 - 26
Acquired clinical resistance to vemurafenib, a selective BRAF(V600E) inhibitor, arises frequently after short-term chemotherapy. Because inhibitions of targets... 
BRAF INHIBITION | METASTATIC MELANOMA | ANTIPROLIFERATIVE ACTIVITY | THERAPY | PLX4032 | ONCOLOGY | ANTICANCER AGENTS | POLYMERIZATION | MUTATIONS | ANTITUMOR-ACTIVITY | CANCER
Journal Article
ONCOGENE, ISSN 0950-9232, 01/2012, Volume 31, Issue 4, pp. 446 - 457
Journal Article
British Journal of Cancer, ISSN 0007-0920, 10/2014, Volume 111, Issue 8, pp. 1625 - 1633
  Melanoma, the most lethal form of skin cancer, is responsible for over 80% of all skin cancer deaths and is highly metastatic, readily spreading to the lymph... 
Molecular Diagnostics | PLX4032 | MMP-1 | vemurafenib | cytokines | tumour microenvironment | chemokines | carcinoma-like associated fibroblasts | stromal fibroblasts
Journal Article